A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01705483
Recruitment Status : Terminated (Based on the results of the Phase 1 data, the company decided not to pursue the development of this drug at this time.)
First Posted : October 12, 2012
Last Update Posted : September 1, 2015
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : June 2014
  Study Completion Date : June 2014